Covis Pharma has launched a Phase III clinical trial to evaluate its asthma drug Alvesco (ciclesonide) for the treatment of non-hospitalised, symptomatic Covid-19 patients aged 12 years and above.
The company, which is based in Luxembourg with operations in Zug, Switzerland, secured the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application of the drug to treat Covid-19.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Designed to assess the drug’s safety and efficacy, the multi-centre, randomised, double-blind, placebo-controlled trial commenced patient enrolment.
